<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3906201</article-id><article-id pub-id-type="pmid">24489961</article-id><article-id pub-id-type="publisher-id">PONE-D-13-30269</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0087773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Mutation</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Immunity to Infections</subject></subj-group></subj-group><subj-group><subject>Genetics of the Immune System</subject><subject>Major Histocompatibility Complex</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Adaptive Immunity</subject></subj-group></subj-group><subj-group><subject>Virology</subject><subj-group><subject>Antivirals</subject><subject>Viral Immune Evasion</subject><subject>Viral Replication</subject></subj-group></subj-group></subj-group><subj-group><subject>Population Biology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Genetics of the Immune System</subject></subj-group></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>Hepatitis</subject><subj-group><subject>Hepatitis C</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="21245" pm="."><plain>Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Naïve Korean Patients Chronically Infected with HCV Genotype 1b </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">HCV NS5B Mutations from Treatment- Naïve Patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dong-Won</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seoung-Ae</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Won</surname><given-names>You-Sub</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Bum-Joon</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<addr-line>Department of Biomedical Sciences, Microbiology and Immunology, and Liver Research Institute, College of Medicine, Seoul National University, Seoul, Korea</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Blackard</surname><given-names>Jason</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Cincinnati College of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>kbumjoon@snu.ac.kr</email></corresp><fn fn-type="COI-statement"><p><text><SENT sid="21246" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="21247" pm="."><plain>Conceived and designed the experiments: DWK SAL BJK. </plain></SENT>
<SENT sid="21248" pm="."><plain>Performed the experiments: DWK. </plain></SENT>
<SENT sid="21249" pm="."><plain>Analyzed the data: DWK BJK. </plain></SENT>
<SENT sid="21250" pm="."><plain>Contributed reagents/materials/analysis tools: SAL HK YSW. </plain></SENT>
<SENT sid="21251" pm="."><plain>Wrote the paper: DWK BJK. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2014</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>e87773</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>© 2014 Kim et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="21252" pm="."><plain>The nonstructural 5B (NS5B) protein of the hepatitis C virus (HCV) with RNA-dependent RNA polymerase (RdRp) activity plays a pivotal role in viral replication. </plain></SENT>
<SENT sid="21253" pm="."><plain>Therefore, monitoring of its naturally occurring mutations is very important for the development of antiviral therapies and vaccines. </plain></SENT>
<SENT sid="21254" pm="."><plain>In the present study, mutations in the partial NS5B gene (492 bp) from 166 quasispecies of 15 genotype-1b (GT) treatment-naïve Korean chronic patients were determined and mutation patterns and frequencies mainly focusing on the T cell epitope regions were evaluated. </plain></SENT>
<SENT sid="21255" pm="."><plain>The mutation frequency within the CD8+ T cell epitopes was significantly higher than those outside the CD8+ T cell epitopes. </plain></SENT>
<SENT sid="21256" pm="."><plain>Of note, the mutation frequency within predicted CD4+ T cell epitopes, a particular mutational hotspot in Korean patients was significantly higher than it was in patients from other areas, suggesting distinctive CD4+ T cell-mediated immune pressure against HCV infection in the Korean population. </plain></SENT>
<SENT sid="21257" pm="."><plain>The mutation frequency in the NS5B region was positively correlated with patients with carrier-stage rather than progressive liver disease (chronic hepatitis, liver cirrhosis and hepatocellular carcinoma). </plain></SENT>
<SENT sid="21258" pm="."><plain>Furthermore, the mutation frequency in four codons (Q309, A333, V338 and Q355) known to be related to the sustained virological response (SVR) and end-of treatment response (ETR) was also significantly higher in Korean patients than in patients from other areas. </plain></SENT>
<SENT sid="21259" pm="."><plain>In conclusion, a high degree of mutation frequency in the HCV GT-1b NS5B region, particularly in the predicted CD4+ T cell epitopes, was found in Korean patients, suggesting the presence of distinctive CD4+ T cell pressure in the Korean population. </plain></SENT>
<SENT sid="21260" pm="."><plain>This provides a likely explanation of why relatively high levels of SVR after a combined therapy of pegylated interferon (PEG-IFN) and ribavirin (RBV) in Korean chronic patients with GT-1b infections are observed. </plain></SENT>
</text></SecTag></p></abstract><funding-group><funding-statement>This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2013-005810). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="21261" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="21262" pm="."><plain>According to the WHO, 3% of the global population is infected with the hepatitis C virus (HCV), with 3–4 million people newly infected each year [1]–[4]. </plain></SENT>
<SENT sid="21263" pm="."><plain>Most HCV infections persist, with up to 80% of all cases leading to chronic hepatitis associated with liver fibrosis, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [5]–[7]. </plain></SENT>
<SENT sid="21264" pm="."><plain>A combinatorial treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) provides good clinical efficacy in patients infected with genotypes (GTs) 2 and 3 but is less efficacious in patients infected with the most prevalent GT-1b, thereby emphasizing the urgent need for more effective specifically targeted antiviral therapies for GT-1b [8]–[11]. </plain></SENT>
</text></p><p><text><SENT sid="21265" pm="."><plain>The HCV RNA-dependent RNA polymerase (RdRp) is an essential enzyme that lacks proofreading activity, thus leading to a population of distinctive but closely related viral variants, termed viral quasispecies, within an infected individual [12]–[14]. </plain></SENT>
<SENT sid="21266" pm="."><plain>Monitoring of the diversity of HCV quasispecies is important for the prediction of liver disease progression as well as HCV treatment outcomes [15]–[19]. </plain></SENT>
<SENT sid="21267" pm="."><plain>Currently, studies regarding HCV quasispecies mainly focus on structural genomic regions; therefore, relatively limited data are available regarding nonstructural regions. </plain></SENT>
<SENT sid="21268" pm="."><plain>Recently, variations in the nonstructural 5B (NS5B) protein, particularly in specific codons, were reported to be positively related to a sustained virological response (SVR) and end-of treatment response (ETR) of patients infected with GT-1b [15], [16]. </plain></SENT>
</text></p><p><text><SENT sid="21269" pm="."><plain>It was also reported that the SVR rate in patients with HCV GT-1b treated with PEG-IFN plus RBV are higher in Asian patients as compared with Caucasians [10], [20]. </plain></SENT>
<SENT sid="21270" pm="."><plain>In particular, previous studies have shown that SVR rates in Korea patients infected with GT-1b range from 56% to 62% [21], [22]. </plain></SENT>
<SENT sid="21271" pm="."><plain>Recently, two SNPs, rs12979860 and rs8099917 of the IL28B gene, showing the strongest association with treatment response, have been reported at a high frequency in Korean patients with HCV GT-1b compared to the frequencies of other ethnic groups [23], [24]. </plain></SENT>
<SENT sid="21272" pm="."><plain>Although prior investigations can partly explain the high SVR rates in Korean patients, other mechanisms may also contribute to this effect. </plain></SENT>
<SENT sid="21273" pm="."><plain>In the present study, to address this issue, we investigated via quasispecies analysis the mutation frequencies and patterns in the partial NS5B from Korean patients infected with HCV GT-1b, as these are known to be related to the SVR rates, </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="21274" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="21275" pm="."><plain>Patients and HCV RNA Extraction </plain></SENT>
</text></title><p><text><SENT sid="21276" pm="."><plain>Serum samples were collected from a total of 73 treatment-naïve HCV-positive patients who visited Seoul National University Hospital in 2003. </plain></SENT>
<SENT sid="21277" pm="."><plain>The clinical statuses of the HCV-positive patients were defined as carrier (C), chronic hepatitis (CH), LC or HCC. </plain></SENT>
<SENT sid="21278" pm="."><plain>General definitions of the C and chronic liver disease types are as follows: the diagnosis of C can be made in the presence of positive anti-HCV antibodies, of a positive HCV RNA by RT-PCR, and of normal alanine aminotransferase (ALT) levels (&lt;40 IU/L, assay dependent) in at least three tests carried out at least two months apart over a period of six months [25], [26]; CH was defined as an elevation of or fluctuation in serum ALT levels over 6 months without any evidence of any other chronic liver disease [27]; LC was diagnosed through evidence of clinically relevant portal hypertension (esophageal varices and/or ascites, splenomegaly with a platelet count of 100,000/mm3) [28], ultrasonographic imaging features suggestive of liver cirrhosis [29], and a histological diagnosis with one of the following features: nodular regeneration, fragmentation of the biopsy with fibrosis at the margins and a wide postnecrotic collapse with an abnormal relationship between portal tracts and central veins, and evidence of active liver-cell hyperplasia [30]. </plain></SENT>
<SENT sid="21279" pm="."><plain>Finally, HCC in cirrhotic patients was diagnosed either through radiological criteria (focal lesion &gt;2 cm with arterial hypervascularization according to two coincident imaging techniques) or through combined criteria (focal lesion &gt;2 cm with arterial hypervascularization according to one imaging technique associated with AFP levels &gt;400 ng/ml) [31]. </plain></SENT>
<SENT sid="21280" pm="."><plain>HCV RNA was purified using the Viral Gene-Spin Viral DNA/RNA Kit (iNtRON Biotechnology Inc., Seongnam, Korea) according to the manufacturer's guideline. </plain></SENT>
<SENT sid="21281" pm="."><plain>This work was approved by the institutional review board of Seoul National University Hospital (IRB No. </plain></SENT>
<SENT sid="21282" pm="."><plain>C-1304-032-479). </plain></SENT>
<SENT sid="21283" pm="."><plain>The experiment was mainly based on the viral RNA extracted from isolates; therefore, the research was done without informed consent and a waiver of informed consent was agreed upon by the IRB. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="21284" pm="."><plain>Quantitative PCR (qPCR) and cDNA synthesis </plain></SENT>
</text></title><p><text><SENT sid="21285" pm="."><plain>A qPCR method was used to analyze viral RNA with an ABI7500 system (Perkin-Elmer Applied Biosystems, Warrington, UK). </plain></SENT>
<SENT sid="21286" pm="."><plain>The primers were designed to amplify the NS2 region and the sequences were as follows: sense primer HCVF (5′-CGA CCA GTA CCA CCA TCC TT-3′) and antisense primer HCVR (5′-AGC ACC TTA CCC AGG CCT AT-3′). </plain></SENT>
<SENT sid="21287" pm="."><plain>For the detection of HCV RNA, the SensiFAST SYBR Lo-ROX kit (Bioline, Taunton, MA, USA) was used according to the manufacturer's instructions. </plain></SENT>
<SENT sid="21288" pm="."><plain>Absolute quantification of extracted HCV RNA relies on the accuracy with the amount of HCV RNA standard measured with a lower limit of detection of 1,350 copies/ml (500 IU/ml) on the basis of earlier research (data not shown) [32], [33]. </plain></SENT>
<SENT sid="21289" pm="."><plain>Viral cDNA synthesis for Reverse-transcriptase (RT) PCR was done using the Maxime RT PreMix kit (iNtRON Biotechnology Inc., Seongnam, Korea) according to its own protocol. </plain></SENT>
</text></p></sec><sec id="s2c"><title><text><SENT sid="21290" pm="."><plain>Nested PCR Amplification </plain></SENT>
</text></title><p><text><SENT sid="21291" pm="."><plain>The nested PCR method and primer pairs to amplify GT-1 to 4 are available in the literature [34]. </plain></SENT>
<SENT sid="21292" pm="."><plain>Briefly, as an example of GT-1b, the first round of amplification was carried out using the sense primer A1b (O/S) (accession no. M62321, positions 8113–8135, 5′ - CTGACRACTAGCTGYGGTAAYAC - 3′) and the antisense primer F1b (O/A) (positions 8678–8699, 5′ - CCTGGAGAGTAACTRTGGAGTG - 3′). </plain></SENT>
<SENT sid="21293" pm="."><plain>The first-round reaction was subjected to 30 cycles of amplification (30 s at 94°C, 30 s at 45°C and 50 s at 68°C) followed by 7 min of extension at 72°C. </plain></SENT>
<SENT sid="21294" pm="."><plain>The second round of amplification was carried out using the sense primer B1b (I/S) (positions 8181–8205, 5′ - GCTCCRGGACTGCACSATGCTCGTG - 3′) and the antisense primer E1b (I/A) (positions 8654–8675, 5′ - AATGCGCTRAGRCCATGGAGTC - 3′) to amplify 495 bp of the GT-1b NS5B region. </plain></SENT>
<SENT sid="21295" pm="."><plain>The second-round reaction was subjected to 30 cycles of amplification (30 s at 93°C, 30 s at 55°C and 1 min at 68°C) followed by 7 min of extension at 72°C. </plain></SENT>
</text></p></sec><sec id="s2d"><title><text><SENT sid="21296" pm="."><plain>Cloning and Sequencing Analysis </plain></SENT>
</text></title><p><text><SENT sid="21297" pm="."><plain>The PCR products of GT-1b were cloned using the TOPO TA Cloning kit (Invitrogen Corporation, Carlsbad, CA, USA). </plain></SENT>
<SENT sid="21298" pm="."><plain>The NS5B regions were sequenced using the M13 primer. </plain></SENT>
<SENT sid="21299" pm="."><plain>For each subject, 10 to 12 subclones were sequenced [35], [36]. </plain></SENT>
<SENT sid="21300" pm="."><plain>Sequencing was conducted using the Applied Biosystems model 377 DNA automatic sequencer (Perkin-Elmer Applied Biosystems, Warrington, UK). </plain></SENT>
<SENT sid="21301" pm="."><plain>If there were sequence variations between the clones of a sample, the dominant sequence at each position was determined as the major sequence. </plain></SENT>
<SENT sid="21302" pm="."><plain>Nucleotides were aligned and their similarities were calculated using the multiple-alignment algorithm in Megalign (DNASTAR, Windows Version 3.12e). </plain></SENT>
<SENT sid="21303" pm="."><plain>A mutation in this study was defined as a sequence different from the consensus sequence of 20 GT-1b reference strains obtained from the LANL HCV database (<ext-link ext-link-type="uri" xlink:href="http://hcv.lanl.gov">http://hcv.lanl.gov</ext-link>) [accession numbers AB442219, AB691953, AF165047, D11168, D13558, D16435, D50485, D85516, D90208, EU256084, EU482859, FJ478453, HQ110091, HQ912958, J238799, L02836, M58335, M96362, S62220 and X61596] [37]. </plain></SENT>
<SENT sid="21304" pm="."><plain>Because at aa 316 and 464, the two types of subclonal amino acids were conserved in each subject, both amino acids were considered to be a consensus sequence [38], [39]. </plain></SENT>
<SENT sid="21305" pm="."><plain>For a further comparison of the analyzed sequences, 45 HCV GT-1b sequences from other countries (China: 15, Japan: 15, Switzerland: 15 and the United States: 15) were also retrieved from the LANL HCV database and relevant nucleotide positions were compared with the consensus sequence of 15 subjects. </plain></SENT>
</text></p></sec><sec id="s2e"><title><text><SENT sid="21306" pm="."><plain>Phylogenetic analysis </plain></SENT>
</text></title><p><text><SENT sid="21307" pm="."><plain>HCV GTs were confirmed by a phylogenetic analysis based on 12 reference strains representing each of the GTs of 1–6 obtained from GenBank [accession numbers AF009606 (1a), AF064490 (5a), AY232745 (2b), D63821 (3a), D90208 (1b), DQ480515 (6a), JX961069 (2a), M58335 (1b), M67463 (1a), S62220 (1b), X61596 (1b) and Y11604 (4a)]. </plain></SENT>
<SENT sid="21308" pm="."><plain>Phylogenetic trees were inferred using the neighbor-joining method [40]. </plain></SENT>
<SENT sid="21309" pm="."><plain>Neighbor-joining was carried out using MEGA version 4.0.2 [41]. </plain></SENT>
<SENT sid="21310" pm="."><plain>The resultant neighbor-joining tree and topology were evaluated by bootstrap analyses based on 1,000 re-samplings. </plain></SENT>
</text></p></sec><sec id="s2f"><title><text><SENT sid="21311" pm="."><plain>Prediction of novel CD4+ T cell epitopes and determination of mutations inside and outside CD4+ or CD8+ T cell epitopes </plain></SENT>
</text></title><p><text><SENT sid="21312" pm="."><plain>15-mer peptides containing an association between a particular HLA class II molecule and the sequenced NS5B with binding capacity &lt;500 mM were screened in silico for the presence of the relevant HLA-binding motif [42]. </plain></SENT>
<SENT sid="21313" pm="."><plain>Mutations within the CD4+ and CD8+ T cell epitopes were defined as a sequence different from the consensus sequence within the four selected CD4+ T cell epitopes with above criteria and six known CD8+ T cell epitopes, respectively, on the basis of previous studies [37], [43]–[45]. </plain></SENT>
<SENT sid="21314" pm="."><plain>Mutations outside the CD4+ or CD8+ T cell epitopes were counted according to the total number of mutations minus the sum of the respective epitope regions. </plain></SENT>
</text></p></sec><sec id="s2g"><title><text><SENT sid="21315" pm="."><plain>Statistical analyses </plain></SENT>
</text></title><p><text><SENT sid="21316" pm="."><plain>The results were expressed as percentages, means ± SD, or as medians (range). </plain></SENT>
<SENT sid="21317" pm="."><plain>The differences between the categorical variables were analyzed using Fisher's exact test or a Chi-square test. </plain></SENT>
<SENT sid="21318" pm="."><plain>For continuous variables, the Student's t-test was used when the data showed a normal distribution, or the Mann-Whitney U test was used when the data was not normally distributed. </plain></SENT>
<SENT sid="21319" pm="."><plain>The level of significance of each test was adjusted for multiple tests via Bonferroni correction. </plain></SENT>
<SENT sid="21320" pm="."><plain>A p-value of &lt;0.05 (two-tailed) was considered to be statistically significant. </plain></SENT>
<SENT sid="21321" pm="."><plain>Statistical analysis of the data was performed using SPSS version 20 (IBM Corp. </plain></SENT>
<SENT sid="21322" pm="."><plain>Armonk, NY, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="21323" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="21324" pm="."><plain>Nested PCR-based distribution of GTs </plain></SENT>
</text></title><p><text><SENT sid="21325" pm="."><plain>Among 73 treatment-naïve samples which were subject to cDNA synthesis, 23 (31.5%) were amplified. </plain></SENT>
<SENT sid="21326" pm="."><plain>The quantification cycle (Cq) values of 50 samples not amplified (33.91±1.55) were significantly lower than those of the 23 amplified samples (32.76±1.17) (p = 0.002). </plain></SENT>
<SENT sid="21327" pm="."><plain>Similar to the serological prevalence, GT-1b (15 patients, 65.2%) and 2 (6 patients, 26.1%) were dominant in Koreans [46]. </plain></SENT>
<SENT sid="21328" pm="."><plain>GT-3a and 4 were amplified in one subject each (4.3%) (Table S1). </plain></SENT>
<SENT sid="21329" pm="."><plain>Clinical details of the GT-1b patients for whom the sequences were amplified are presented in Table S2. </plain></SENT>
</text></p></sec><sec id="s3b"><title><text><SENT sid="21330" pm="."><plain>Phylogenetic analysis of GT-1b and its characteristics </plain></SENT>
</text></title><p><text><SENT sid="21331" pm="."><plain>A phylogenetic analysis based on the 492bp GT-1b sequenced NS5B region of randomly selected subclones showed distinct sequence variation between each subject (Fig. 1). </plain></SENT>
<SENT sid="21332" pm="."><plain>All 15 subjects belonged to GT-1b. </plain></SENT>
<SENT sid="21333" pm="."><plain>12 subjects with N316/E464 and three subjects with C316/Q464 were phylogenetically segregated, showing high bootstrap values (75%). </plain></SENT>
<SENT sid="21334" pm="."><plain>The C316/Q464 group had significantly lower Cq values [C316/Q464 (31.69±0.92) vs. N316/E464 (32.28±1.05), p = 0.033] and exclusively showed advanced liver disease (CH + LC + HCC) (100%) compared to the other group (48.1%, p = 0.001) at the subclonal level (Table 1, Table S3). </plain></SENT>
<SENT sid="21335" pm="."><plain>This finding indicates a positive correlation between viral replication and the clinical severity of liver disease. </plain></SENT>
<SENT sid="21336" pm="."><plain>The nucleotide sequence of 166 subclones is available in the GenBank nucleotide sequence databases with the following accession numbers: KF422017-KF422027. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0087773-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="21337" pm="."><plain>Phylogenic tree of 492bp of the GT-1b NS5B region. </plain></SENT>
</text></title><p><text><SENT sid="21338" pm="."><plain>Genetic distances were estimated using the Kimura two-parameter matrix and the phylogenetic tree was constructed using the neighbor-joining method. </plain></SENT>
<SENT sid="21339" pm="."><plain>The percentages indicated at the nodes represent bootstrap levels supported by 1,000 re-sampled data sets. </plain></SENT>
<SENT sid="21340" pm="."><plain>Bootstrap values of &lt;70% are not shown. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0087773.g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0087773-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="21341" pm="."><plain>Mutation frequency at the major codons including antiviral resistance and SVR-related codons in the sequenced NS5B region. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t001-1" xlink:href="pone.0087773.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21342" pm="."><plain>Amino acid variant types </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21343" pm="."><plain>No. of mutations (Total = 166) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21344" pm="."><plain>Rate (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21345" pm="."><plain>No. of patient </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21346" pm="."><plain>Mutation typea </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21347" pm="."><plain>Note (Reference) </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21348" pm="."><plain>Q309R </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21349" pm="."><plain>96 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21350" pm="."><plain>57.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21351" pm="."><plain>15 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21352" pm="."><plain>Diverse </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21353" pm="."><plain>SVR and ETR 27%, NR: 9% in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21354" pm="."><plain>C316Nb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21355" pm="."><plain>133 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21356" pm="."><plain>80.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21357" pm="."><plain>12 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21358" pm="."><plain>Conserved </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21359" pm="."><plain>63.3% with C316N/Y in patients treated with IFN/RBV in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21360" pm="."><plain>A333E/V </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21361" pm="."><plain>16 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21362" pm="."><plain>9.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21363" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21364" pm="."><plain>Conserved (E), Diverse (V) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21365" pm="."><plain>SVR and ETR 23%, NR: 9% in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21366" pm="."><plain>S335N </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21367" pm="."><plain>63 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21368" pm="."><plain>38.0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21369" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21370" pm="."><plain>Diverse </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21371" pm="."><plain>29.6% with S335A/N in patients treated with IFN/RBV in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21372" pm="."><plain>V338A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21373" pm="."><plain>46 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21374" pm="."><plain>27.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21375" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21376" pm="."><plain>Diverse </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21377" pm="."><plain>SVR and ETR 18%, NR: 5% in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21378" pm="."><plain>P353L </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21379" pm="."><plain>57 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21380" pm="."><plain>34.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21381" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21382" pm="."><plain>Diverse </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21383" pm="."><plain>17.3% with S335A/N in patients treated with IFN/RBV in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21384" pm="."><plain>Q355K/R </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21385" pm="."><plain>34 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21386" pm="."><plain>20.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21387" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21388" pm="."><plain>Conserved </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21389" pm="."><plain>SVR and ETR 25%, NR: 5% in Japan (15) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21390" pm="."><plain>E440D/G/K </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21391" pm="."><plain>40 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21392" pm="."><plain>24.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21393" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21394" pm="."><plain>Conserved (D), Diverse (G/K) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21395" pm="."><plain>Immunosuppressant resistant mutation [58] </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21396" pm="."><plain>C451H/T/Y </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21397" pm="."><plain>46 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21398" pm="."><plain>27.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21399" pm="."><plain>6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21400" pm="."><plain>Conserved (T/Y), Diverse (H) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21401" pm="."><plain>The frequency of 2 AA are almost same in Japan (16) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21402" pm="."><plain>E464Qb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21403" pm="."><plain>33 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21404" pm="."><plain>19.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21405" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21406" pm="."><plain>Conserved </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21407" pm="."><plain>The frequency of 2 AA are almost same in Japan (16) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p><text><SENT sid="21408" pm="."><plain>a. ‘Diverse’ indicates the mutation type of the coexistence with the wild type in a quasispecies distribution of a subject. </plain></SENT>
<SENT sid="21409" pm="."><plain>Otherwise, ‘Conserved’ indicates the presence of only mutation types alone without the wild type in a quasispecies distribution of a subject. </plain></SENT>
</text></p></fn><fn id="nt102"><label/><p><text><SENT sid="21410" pm="."><plain>b. </plain></SENT>
<SENT sid="21411" pm="."><plain>C316/Q464 and N316/E464 were found in an exclusive manner. </plain></SENT>
<SENT sid="21412" pm="."><plain>All the 33 subclones with the C316/Q464 type were found in patients with advanced liver disease, but not in Cs. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3c"><title><text><SENT sid="21413" pm="."><plain>Distribution of mutations in the sequenced NS5B region </plain></SENT>
</text></title><p><text><SENT sid="21414" pm="."><plain>The distribution of the mutations from the sequenced GT-1b NS5B region aa 164 is shown in Fig. 2. </plain></SENT>
<SENT sid="21415" pm="."><plain>There were six known CD8+ T cell epitopes (Table S4) [37], [43]–[45], and the mutation frequencies inside the CD8+ T cell epitope regions (2.9%) were significantly higher than those outside the epitope regions (2.3%, p = 0.001). </plain></SENT>
<SENT sid="21416" pm="."><plain>The mutation frequencies inside the predicted CD4+ T cell epitopes (4.8%) were significantly higher than those outside the CD4+ T cell epitope (1.4%) and were even higher than those inside the known CD8+ T cell epitopes (p&lt;0.001) (Table S5). </plain></SENT>
<SENT sid="21417" pm="."><plain>We designated the region including the aa 333–355 section of the CD4+ T cell epitopes as a mutational hotspot, as which an extraordinary high mutation frequency (6.7%) was observed (Fig. 2). </plain></SENT>
<SENT sid="21418" pm="."><plain>Of note, the region was predicted to have high binding affinity for the various MHC class II HLA types prevalent in Koreans, raising the possibility that there may be distinctive MHC class II restricted immune pressure against HCV GT-1b in the mutational hotspot (Table 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0087773-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="21419" pm="."><plain>Distribution and frequencies of the amino acid mutations in the NS5B AA 308–471 regions. </plain></SENT>
</text></title><p><text><SENT sid="21420" pm="."><plain>The blue-shaded regions are the known MHC class I restricted regions and the red-lined regions are regions expected to be Korean-specific CD4+ epitope-binding regions. </plain></SENT>
<SENT sid="21421" pm="."><plain>The region between the dotted lines is a mutational hotspot. </plain></SENT>
<SENT sid="21422" pm="."><plain>The arrow indicates amino acid substitution related to IFN/RBV and other agents in HCV and the asterisks denote the novel mutations found in this study. </plain></SENT>
<SENT sid="21423" pm="."><plain>The letters C and D indicate ‘conserved’ and ‘diverse’ in the subclones, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0087773.g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone-0087773-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="21424" pm="."><plain>Comparison of mutation rates between the CD4+ and CD8+ T cell epitope regions. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t002-2" xlink:href="pone.0087773.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21425" pm="."><plain>Regions (n = 27,224) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21426" pm="."><plain>No. of mutations/No. of codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21427" pm="."><plain>Mutation rate (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21428" pm="."><plain>P-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21429" pm="."><plain>Outside known CD8+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21430" pm="."><plain>425/18,758 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21431" pm="."><plain>2.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21432" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21433" pm="."><plain>Inside known CD8+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21434" pm="."><plain>249/8,466 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21435" pm="."><plain>2.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21436" pm="."><plain>0.001a </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21437" pm="."><plain>Outside predicted CD4+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21438" pm="."><plain>250/18,426 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21439" pm="."><plain>1.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21440" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21441" pm="."><plain>Predicted CD4+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21442" pm="."><plain>424/8,798 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21443" pm="."><plain>4.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21444" pm="."><plain>&lt;0.001b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21445" pm="."><plain>Mutational hotspot_1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21446" pm="."><plain>254/3,818 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21447" pm="."><plain>6.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21448" pm="."><plain>&lt;0.001b </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p><text><SENT sid="21449" pm="."><plain>a. </plain></SENT>
<SENT sid="21450" pm="."><plain>P-values were determined by a comparison of mutation rates of inside and outside of the CD8+ T cell epitopes. </plain></SENT>
</text></p></fn><fn id="nt104"><label/><p><text><SENT sid="21451" pm="."><plain>b. </plain></SENT>
<SENT sid="21452" pm="."><plain>P-values (&lt;0.001) were obtained by a comparison of the mutation rates of outside of the CD4+ T cell epitopes as well as inside the CD8+ T cell epitopes. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3d"><title><text><SENT sid="21453" pm="."><plain>Comparison of synonymous (dS) and nonsynonymous mutations (dN) according to the NS5B region </plain></SENT>
</text></title><p><text><SENT sid="21454" pm="."><plain>The distinctive CD4+ T cell-mediated immune pressure was examined by comparing dN to dS. </plain></SENT>
<SENT sid="21455" pm="."><plain>The dN/dS ratio inside the known CD8+ T cell epitopes (0.29) was slightly higher than that of the outside (0.21) region with dN frequencies of 2.9% and 2.3%, respectively. </plain></SENT>
<SENT sid="21456" pm="."><plain>The dN/dS ratio inside the predicted CD4+ T cell epitopes (0.49) was statistically higher than that outside (0.13), with dN frequencies of 4.8% and 1.4%, respectively, although the dS frequency outside the predicted CD4+ T cell epitopes was higher at a statistically significant level. </plain></SENT>
<SENT sid="21457" pm="."><plain>The odds ratio of the dN inside and outside the predicted CD4+ T cell epitopes was 3.55. </plain></SENT>
<SENT sid="21458" pm="."><plain>In the mutational hotspot, dN frequencies (11.1%) were found to be higher than dS frequencies (4.8%), resulting in an elevated dN/dS ratio (1.4). </plain></SENT>
<SENT sid="21459" pm="."><plain>This suggests there are strong MHC class II restricted immune pressures against HCV NS5B in chronic Korean patients (Table 3). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0087773-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="21460" pm="."><plain>Frequencies of dN and dS according to the NS5B region. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t003-3" xlink:href="pone.0087773.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21461" pm="."><plain>Regions </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21462" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21463" pm="."><plain>Inside </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21464" pm="."><plain>Outside </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21465" pm="."><plain>Odds ratio </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21466" pm="."><plain>Known CD8+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21467" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21468" pm="."><plain>8,466 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21469" pm="."><plain>18,758 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21470" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21471" pm="."><plain>(51 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21472" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21473" pm="."><plain>249 (2.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21474" pm="."><plain>426 (2.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21475" pm="."><plain>1.30a </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21476" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21477" pm="."><plain>868 (10.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21478" pm="."><plain>1,992 (10.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21479" pm="."><plain>0.97 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21480" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21481" pm="."><plain>0.29 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21482" pm="."><plain>0.21 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21483" pm="."><plain>1.34 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21484" pm="."><plain>Known CD4+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21485" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21486" pm="."><plain>8,798 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21487" pm="."><plain>18,426 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21488" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21489" pm="."><plain>(53 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21490" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21491" pm="."><plain>424 (4.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21492" pm="."><plain>250 (1.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21493" pm="."><plain>3.55b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21494" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21495" pm="."><plain>863 (9.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21496" pm="."><plain>1,997 (10.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21497" pm="."><plain>0.91c </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21498" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21499" pm="."><plain>0.49 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21500" pm="."><plain>0.13 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21501" pm="."><plain>3.92 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21502" pm="."><plain>Mutational hotspot </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21503" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21504" pm="."><plain>3,818 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21505" pm="."><plain>23,406 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21506" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21507" pm="."><plain>(23 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21508" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21509" pm="."><plain>254 (6.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21510" pm="."><plain>420 (1.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21511" pm="."><plain>3.71b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21512" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21513" pm="."><plain>182 (4.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21514" pm="."><plain>2,678 (11.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21515" pm="."><plain>0.42b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21516" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21517" pm="."><plain>1.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21518" pm="."><plain>0.16 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21519" pm="."><plain>8.90 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p><text><SENT sid="21520" pm="."><plain>a. p = 0.001; </plain></SENT>
</text></p></fn><fn id="nt106"><label/><p><text><SENT sid="21521" pm="."><plain>b. p&lt;0.001; </plain></SENT>
</text></p></fn><fn id="nt107"><label/><p><text><SENT sid="21522" pm="."><plain>c. p = 0.01. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3e"><title><text><SENT sid="21523" pm="."><plain>Comparisons of dS and dN in the NS5B region between Korean patients and patients from other countries </plain></SENT>
</text></title><p><text><SENT sid="21524" pm="."><plain>To examine whether there was distinctive immune pressure against HCV NS5B at the CD4+ T cell level in Koreans, we compared dS and dN in the NS5B region between 15 Korean patients and 60 patients from other countries (China: 15, Japan: 15, Switzerland: 15 and the United States: 15). </plain></SENT>
<SENT sid="21525" pm="."><plain>In the Koreans subjects, we used the consensus sequences of NS5B from more than 10 subclones of patients. </plain></SENT>
<SENT sid="21526" pm="."><plain>For the patients from other countries, we used sequences retrieved from the LANL HCV database. </plain></SENT>
<SENT sid="21527" pm="."><plain>In the NS5B region, the dN/dS ratio for the Korean subjects (0.23) was higher than it was for those from other countries (1.4) with statistical support (p = 0.002). </plain></SENT>
<SENT sid="21528" pm="."><plain>The dN frequency (3.1) in the known CD8+ T cell epitopes from Korean patients was higher than that for the patients from other countries (2.1), but the difference was not statistically significant (p = 0.078). </plain></SENT>
<SENT sid="21529" pm="."><plain>However, the dN frequency (4.5%) in the predicted CD4+ T cell epitope regions in the Korean patients was significantly higher than that in those from other countries (2.2%) (p&lt;0.001). </plain></SENT>
<SENT sid="21530" pm="."><plain>The dN/dS ratios in the predicted CD4+ T cell epitope regions were higher in the Koreans (0.52) by nearly twofold compared to those of the patients from other areas (0.26). </plain></SENT>
<SENT sid="21531" pm="."><plain>In particularly, the difference in the dN frequency between the Koreans (6.4%) and the patients from other countries (2.3%) was more pronounced in the mutational hotspot. </plain></SENT>
<SENT sid="21532" pm="."><plain>Collectively, these results suggest the presence of distinctive CD4+ T cell mediated immune pressure against HCV NS5B in Koreans (Table 4). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0087773-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t004</object-id><label>Table 4</label><caption><title><text><SENT sid="21533" pm="."><plain>Comparison of the frequencies of dN and dS of the NS5B regions between 15 Korean patients consensus sequence and patients from other countries. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t004-4" xlink:href="pone.0087773.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21534" pm="."><plain>Regions </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21535" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21536" pm="."><plain>Korean (n = 15) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21537" pm="."><plain>Other countriesa (n = 60) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21538" pm="."><plain>Odds ratio </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21539" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21540" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21541" pm="."><plain>2,460 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21542" pm="."><plain>9,840 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21543" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21544" pm="."><plain>(164 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21545" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21546" pm="."><plain>57 (2.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21547" pm="."><plain>142 (1.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21548" pm="."><plain>1.61b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21549" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21550" pm="."><plain>252 (10.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21551" pm="."><plain>914 (9.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21552" pm="."><plain>1.10 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21553" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21554" pm="."><plain>0.23 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21555" pm="."><plain>0.16 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21556" pm="."><plain>1.46 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21557" pm="."><plain>Known CD8+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21558" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21559" pm="."><plain>765 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21560" pm="."><plain>3,060 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21561" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21562" pm="."><plain>(51 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21563" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21564" pm="."><plain>24 (3.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21565" pm="."><plain>63 (2.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21566" pm="."><plain>1.52c </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21567" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21568" pm="."><plain>65 (8.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21569" pm="."><plain>290 (9.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21570" pm="."><plain>0.90 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21571" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21572" pm="."><plain>0.37 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21573" pm="."><plain>0.22 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21574" pm="."><plain>1.70 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21575" pm="."><plain>Predicted CD4+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21576" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21577" pm="."><plain>795 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21578" pm="."><plain>3,180 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21579" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21580" pm="."><plain>(53 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21581" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21582" pm="."><plain>36 (4.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21583" pm="."><plain>69 (2.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21584" pm="."><plain>2.12d </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21585" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21586" pm="."><plain>69 (8.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21587" pm="."><plain>261 (8.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21588" pm="."><plain>1.06 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21589" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21590" pm="."><plain>0.52 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21591" pm="."><plain>0.26 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21592" pm="."><plain>1.97 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21593" pm="."><plain>Mutational hotspot </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21594" pm="."><plain>No. of Codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21595" pm="."><plain>345 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21596" pm="."><plain>1,380 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21597" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21598" pm="."><plain>(23 AA) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21599" pm="."><plain>dN (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21600" pm="."><plain>22 (6.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21601" pm="."><plain>32 (2.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21602" pm="."><plain>2.75d </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21603" pm="."><plain>dS (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21604" pm="."><plain>16 (4.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21605" pm="."><plain>53 (3.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21606" pm="."><plain>1.21 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="21607" pm="."><plain>dN/dS ratio </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21608" pm="."><plain>1.38 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21609" pm="."><plain>0.60 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21610" pm="."><plain>2.28 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><label/><p><text><SENT sid="21611" pm="."><plain>a. </plain></SENT>
<SENT sid="21612" pm="."><plain>China: 15, Japan: 15, Switzerland: 15 and the United States: 15. </plain></SENT>
</text></p></fn><fn id="nt109"><label/><p><text><SENT sid="21613" pm="."><plain>b. p = 0.002; </plain></SENT>
</text></p></fn><fn id="nt110"><label/><p><text><SENT sid="21614" pm="."><plain>c: p = 0.078; </plain></SENT>
</text></p></fn><fn id="nt111"><label/><p><text><SENT sid="21615" pm="."><plain>d: p&lt;0.001. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3f"><title><text><SENT sid="21616" pm="."><plain>Correlation between NS5B mutations and the severity of liver disease </plain></SENT>
</text></title><p><text><SENT sid="21617" pm="."><plain>The overall mutation frequency of the entire NS5B region in C (2.8%) was significantly higher than in the comparison group, patients with CH, those with liver cirrhosis LC and those with HCC (2.2%) (p = 0.002). </plain></SENT>
<SENT sid="21618" pm="."><plain>The mutation frequency in known CD8+ T cell epitopes was also significantly higher in C than in the comparison group [C (3.4%) vs. CH + LC + HCC (2.6%), p = 0.05]. </plain></SENT>
<SENT sid="21619" pm="."><plain>This tendency was also found in the predicted CD4+ T cell epitopes [C (5.7%) vs. CH + LC + HCC (4.2%), p = 0.001] and in the mutational hotspot [C (7.7%) vs. CH + LC + HCC (5.9%), p = 0.004] with an increased frequency of mutations at a statistically significant level. </plain></SENT>
<SENT sid="21620" pm="."><plain>This shows that increases in the mutation rate in the NS5B region are negatively correlated with the progression of liver disease in chronic hepatitis C patients (Table 5). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0087773-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t005</object-id><label>Table 5</label><caption><title><text><SENT sid="21621" pm="."><plain>Comparison of the mutation rates in NS5B regions according to the clinical status of liver disease. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t005-5" xlink:href="pone.0087773.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21622" pm="."><plain>Regions (n = 27,224) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21623" pm="."><plain>C (%)/No. of codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21624" pm="."><plain>CH+LC+HCC (%)/No. of codons </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21625" pm="."><plain>P-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21626" pm="."><plain>Total </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21627" pm="."><plain>320 (2.8)/11,316 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21628" pm="."><plain>354 (2.2)/15,908 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21629" pm="."><plain>0.002a </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21630" pm="."><plain>Known CD8+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21631" pm="."><plain>119 (3.4)/3,519 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21632" pm="."><plain>130 (2.6)/4,947 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21633" pm="."><plain>0.05 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21634" pm="."><plain>Predicted CD4+ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21635" pm="."><plain>208 (5.7)/3,657 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21636" pm="."><plain>216 (4.2)/5,141 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21637" pm="."><plain>0.001a </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21638" pm="."><plain>Mutational hotspot </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21639" pm="."><plain>122 (7.7)/1,587 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21640" pm="."><plain>132 (5.9)/2,231 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21641" pm="."><plain>0.004a </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt112"><label/><p><text><SENT sid="21642" pm="."><plain>a. </plain></SENT>
<SENT sid="21643" pm="."><plain>Statistically significant after a Bonferroni post hoc analysis (p&lt;0.05). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3g"><title><text><SENT sid="21644" pm="."><plain>Mutation frequency in codons related to SVR and ETR in Korean patients </plain></SENT>
</text></title><p><text><SENT sid="21645" pm="."><plain>Mutations at the 309, 333, 338 and 355 codons are reportedly related to SVR and ETR groups as compared to non-responders (NR) [15]. </plain></SENT>
<SENT sid="21646" pm="."><plain>Interestingly, a very high mutation rate in four SVR-related codons was found in Korean treatment-naïve patients, with an average mutation frequency of 28.9% (192/664) in the quasispecies distributions. </plain></SENT>
<SENT sid="21647" pm="."><plain>Of note, the average mutation frequency (31.7%) in four codons as calculated from 15 Korean patients was significantly higher than any of the other regions, including that from Japan (Table 6). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0087773-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t006</object-id><label>Table 6</label><caption><title><text><SENT sid="21648" pm="."><plain>Comparison of mutation rates in four SVR-related codons (309, 333, 338 and 355) in the NS5B region between 15 Korean consensus sequence and patients from other countries. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0087773-t006-6" xlink:href="pone.0087773.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21649" pm="."><plain>Countries (n = 15) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21650" pm="."><plain>No. of mutations (n = 60) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21651" pm="."><plain>Mutation rate (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21652" pm="."><plain>P-valuea </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21653" pm="."><plain>Korea </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21654" pm="."><plain>19 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21655" pm="."><plain>31.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21656" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21657" pm="."><plain>China </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21658" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21659" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21660" pm="."><plain>&lt;0.001b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21661" pm="."><plain>Japan </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21662" pm="."><plain>7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21663" pm="."><plain>11.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21664" pm="."><plain>0.014 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21665" pm="."><plain>Switzerland </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21666" pm="."><plain>3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21667" pm="."><plain>5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21668" pm="."><plain>&lt;0.001b </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="21669" pm="."><plain>United States </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21670" pm="."><plain>1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21671" pm="."><plain>1.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="21672" pm="."><plain>&lt;0.001b </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt113"><label/><p><text><SENT sid="21673" pm="."><plain>a. </plain></SENT>
<SENT sid="21674" pm="."><plain>P-values were determined by a comparison with the mutation rate from 15 Korean consensus sequences. </plain></SENT>
</text></p></fn><fn id="nt114"><label/><p><text><SENT sid="21675" pm="."><plain>b. </plain></SENT>
<SENT sid="21676" pm="."><plain>Statistically significant after a Bonferroni post hoc analysis (p&lt;0.05). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="21677" pm="."><plain>A quasispecies analysis showed a total of 10 mutations, including SVR and antiviral resistance in the sequenced NS5B region. </plain></SENT>
<SENT sid="21678" pm="."><plain>These can be divided into two distinct groups. </plain></SENT>
<SENT sid="21679" pm="."><plain>One is the diverse (D) type, which coexists with other quasispecies members in a patient, and the other is made up of conserved (C) types which exist alone without a quasispecies counterpart in a patient (Fig. 2, Table 1). </plain></SENT>
<SENT sid="21680" pm="."><plain>The coexistence of diverse quasispecies at a specific codon may be indirect evidence of an important target for immune pressure or/and viral fitness. </plain></SENT>
<SENT sid="21681" pm="."><plain>Notably, the coexistence of Q and R at codon 309, located in one of the CD8+ T cell epitopes (aa 308 and 315), was found in all 15 Korean subjects via a quasispecies distribution analysis; this may be due to the distinct CD8+ T cell immune pressure against a region between aa 308 and 315 among Koreans (Table S6). </plain></SENT>
<SENT sid="21682" pm="."><plain>In addition, there were other D type mutations: A333V, S335N, V338A, P353L, E440G/K and C451H. </plain></SENT>
<SENT sid="21683" pm="."><plain>On the other hand, there were only three C types of mutations (C316N, Q355K/R and E464Q). </plain></SENT>
<SENT sid="21684" pm="."><plain>Interestingly, in all the three C-type mutations, significantly different Cq values between two counterparts in the respective mutation type were found (Table S3). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="21685" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="21686" pm="."><plain>The presence of distinct HLA types among an ethnic group could lead to distinct MHC class I or II restricted immune pressures within its population [37], [43], [44], [47]. </plain></SENT>
<SENT sid="21687" pm="."><plain>Therefore, the frequency and patterns of escape variants against structural and nonstructural HCV proteins reflect the background HLA types among an ethnic group [48], [49]. </plain></SENT>
<SENT sid="21688" pm="."><plain>The aim of the present study is to investigate the background mutation frequency and patterns of HCV NS5B, reportedly related to a high SVR, from treatment-naïve Korean patients chronically infected with GT-1b in an effort to explain the high SVR in Korean patients. </plain></SENT>
<SENT sid="21689" pm="."><plain>The significant findings of this study are discussed below. </plain></SENT>
</text></p><p><text><SENT sid="21690" pm="."><plain>First, the entire mutation frequency in the sequenced NS5B region was positively correlated with Cs but not with patients showing disease progression (CH, LC and HCC) [C (2.8%) vs. CH + LC + HCC (2.2%), p = 0.002]. </plain></SENT>
<SENT sid="21691" pm="."><plain>Furthermore, similar mutation frequencies were noted within both the CD4+ (p = 0.001) and CD8+ T cell epitope regions (p = 0.05) (Table 5). </plain></SENT>
<SENT sid="21692" pm="."><plain>This suggests that the accumulation of multiple mutations in NS5B may be induced by vigorous and multi-specific immune pressure in the HCV-acute infection phase and may lead to the functional abnormality of HCV RdRp activity, resulting in the attenuation of HCV pathogenic potentials [19]. </plain></SENT>
<SENT sid="21693" pm="."><plain>This strongly supports previous results which showed that mutations in NS5B were related to the high SVR and EVR of GT-1b chronically infected patients [15]. </plain></SENT>
</text></p><p><text><SENT sid="21694" pm="."><plain>Second, a pronounced dN frequency in the predicted CD4+ T cell epitopes in the NS5B region [Korean (4.5%) vs. those of patients from other countries (2.1%), p = 0.001], particularly in the mutational hotspot [Korean (6.4%) vs. other countries (3.1%), p = 0.01], was found in Korean patients but not in patients from other areas (Table 4). </plain></SENT>
<SENT sid="21695" pm="."><plain>This suggests that there is distinct intrahepatic MHC class II restricted immune pressure at least against HCV NS5B among the Korean population [19]. </plain></SENT>
<SENT sid="21696" pm="."><plain>Broadly directed virus-specific immune pressure at the CD4+ T cell level was recently reported to play a very pivotal role in spontaneous resolution at a very early phase of HCV-acute infection [50]. </plain></SENT>
<SENT sid="21697" pm="."><plain>Furthermore, the presence of the multi-specific CD4+ T cell response against HCV can aid not only the induction of a vigorous antiviral CD8+ T cell response but also antibody production for the inhibition of the spread of the virus [51]. </plain></SENT>
<SENT sid="21698" pm="."><plain>Particularly, because three codons (A333, V338 and Q355) out of four reported to be related to the high SVR are located in the mutational hotspot, the acquisition of mutations within this region induced by the distinctive Korean immune pressure at the CD4+ T cell level may contribute to the high SVR found in Korean patients infected with GT-1b. </plain></SENT>
<SENT sid="21699" pm="."><plain>In fact, the prediction of the MHC class II HLA allele showed that a region of the CD4+ T cell epitope from NS5B, covering aa 333 to 347, one of two predicted epitopes comprising the mutational hotspot, has high binding affinity for most HLA DRB1 alleles prevalent in Korean populations [52]. </plain></SENT>
<SENT sid="21700" pm="."><plain>In addition, HLA DQB1 03:01 and 03:02, prevalent at frequencies higher than 10% in Koreans, also are noted to be associated with viral clearance [53]–[55]. </plain></SENT>
<SENT sid="21701" pm="."><plain>Our previous study also showed that there are distinct mutation patterns and a very high mutation frequency of the CD4+ T cell epitopes of the HBV preC/Core region in chronic Korean patients, strongly supporting the hypothesis of this study [56]. </plain></SENT>
</text></p><p><text><SENT sid="21702" pm="."><plain>Third, the frequency of dN within the CD8+ T cell epitope region of NS5B was significantly higher than that outside the CD8+ T cell epitope region [inside CD8+ (2.9%) vs. outside (2.3%), p = 0.001], suggesting the presence of immune pressure at the CD8+ T cell level against HCV NS5B among Korean patients, as shown in patients from other areas (Table 3) [37], [44], [47], [57]. </plain></SENT>
<SENT sid="21703" pm="."><plain>However, pronounced differences in the mutation frequency between six regions of CD8+ T cell epitopes were found. </plain></SENT>
<SENT sid="21704" pm="."><plain>Two of the six CD8+ T cell epitopes (308 to 315 aa and 451 to 459) with high binding affinity to two HLA allele types, HLA-A02:01 and HLA-A24:02, prevalent in Koreans, showed a higher dN frequency compared to other epitopes [308–315: 96 (7.2%) and 451–459: 49 (3.3%)], suggesting the presence of distinct MHC class I restricted immune pressure in Korean patients [52]. </plain></SENT>
<SENT sid="21705" pm="."><plain>Particularly, it is noteworthy that the extraordinary high dN/dS ratio (2.04) found in a region of the CD8+ T cell epitope covering codons 308 to 315, was mainly due to the presence of frequent mutations in codon 309, one of four codons related to SVR rates (Table S4, Fig. 2). </plain></SENT>
<SENT sid="21706" pm="."><plain>The mutation type, Q309R, is known to be frequently mutated in NS5B, particularly in Asian patients. </plain></SENT>
<SENT sid="21707" pm="."><plain>However, even compared to Japanese patients, also an Asian country like Korea, the strikingly high mutation frequency of Q309R was observed in only the Korean patients [15], [16]. </plain></SENT>
<SENT sid="21708" pm="."><plain>All of the 15 patients harbored this mutation in their quasispecies distribution and more than half (96/166, 57.8%) of all quasispecies from the 15 patients had the mutation type R309. </plain></SENT>
<SENT sid="21709" pm="."><plain>Interestingly, the co-existence of both mutated and wild types, not exclusive of the existence of one type alone, was found in all 15 patients, suggesting the advantage of the coexistence of two variants in a patient over the exclusive existence of either type alone in an escape of host immune surveillance or viral fitness (Table S6). </plain></SENT>
<SENT sid="21710" pm="."><plain>Therefore, the high frequency of the Q309R mutation in Korean patients may be induced by CD8+ T cell immune pressure which may in part provide a likely explanation for the high SVR rates in Koreans. </plain></SENT>
</text></p><p><text><SENT sid="21711" pm="."><plain>Finally, it is well known that mutations in NS5B can affect the HCV replication capacity [19]. </plain></SENT>
<SENT sid="21712" pm="."><plain>We found a total of three types of mutations (C316N, Q355K/R and E464Q) which had a significant effect on HCV replication (Cq value: C316N and E464Q p = 0.033, Q355K/R p = 0.003) (Table S3). </plain></SENT>
<SENT sid="21713" pm="."><plain>Interestingly, our quasispecies analysis showed that two polymorphisms in aa 316, C316 and N316, were strongly related to two polymorphisms in codon 464, Q464 and E464, respectively, in an exclusive manner (Figure 1). </plain></SENT>
<SENT sid="21714" pm="."><plain>The type with both C316 and Q464 signatures showed a significantly higher HCV replication capacity and was more related to patients with advanced liver disease compared to the type with both the N316 and E464 signatures. </plain></SENT>
<SENT sid="21715" pm="."><plain>The exclusive combination of the SNPs of two codons may be due to the structural constraint of NS5B. </plain></SENT>
<SENT sid="21716" pm="."><plain>Furthermore, the coexistence of both types (C316/Q464 and N316/E464) was not found in any patients, suggesting that these two types may be from completely different resources and not a different quasispecies version induced by immune pressure from a patient. </plain></SENT>
<SENT sid="21717" pm="."><plain>Our data showing phylogenetic segregation between the two types also supports the above hypothesis. </plain></SENT>
</text></p><p><text><SENT sid="21718" pm="."><plain>Our study has three potential limitations. </plain></SENT>
<SENT sid="21719" pm="."><plain>First, the nested PCR protocol used in this study showed low sensitivity, with the amplification of only 23 samples out of 73 samples (31.5%). </plain></SENT>
<SENT sid="21720" pm="."><plain>The strategies for the nested PCR protocol including primer sets and a PCR condition should be modified in the future study. </plain></SENT>
<SENT sid="21721" pm="."><plain>Particularly, PCR negative amplifications were found with high frequencies in samples with lower HCV viral loads, suggesting novel nested PCR protocol to increase the degree of sensitivity should be applied in a future study. </plain></SENT>
<SENT sid="21722" pm="."><plain>Second, the modest population size (15 patients) is relatively small to lead to a meaningful conclusion about the relationship between NS5B mutations and liver disease progression. </plain></SENT>
<SENT sid="21723" pm="."><plain>Third, as single-genome amplification and an end-point dilution strategy were not utilized, the cloning strategy employed in this study is limited when used to represent genuine viral quasispecies in serum samples. </plain></SENT>
</text></p><p><text><SENT sid="21724" pm="."><plain>In conclusion, our data suggest that the distinct MHC class II restricted immune pressure against HCV NS5B in Korean patients leads to a pronounced high mutation frequency and distinct mutation patterns in HCV NS5B in Korean patients. </plain></SENT>
<SENT sid="21725" pm="."><plain>This finding provides important insight into the high SVR and ETR rates during the treatment of GT-1b infected Korean patients. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="21726" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0087773.s001"><label>Table S1</label><caption><p><text><SENT sid="21727" pm="."><plain>Distribution of amplified subjects by PCR targeting NS5B sequences. </plain></SENT>
</text></p><p><text><SENT sid="21728" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s001.docx"><caption><p><text><SENT sid="21729" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s002"><label>Table S2</label><caption><p><text><SENT sid="21730" pm="."><plain>Clinical features of 15 Korean patients in this study. </plain></SENT>
</text></p><p><text><SENT sid="21731" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s002.docx"><caption><p><text><SENT sid="21732" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s003"><label>Table S3</label><caption><p><text><SENT sid="21733" pm="."><plain>Comparison of Cq values between types at the major codons including antiviral resistance and SVR related in the sequenced NS5B region. </plain></SENT>
</text></p><p><text><SENT sid="21734" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s003.docx"><caption><p><text><SENT sid="21735" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s004"><label>Table S4</label><caption><p><text><SENT sid="21736" pm="."><plain>Comparison of amino acid sequences, dominant HLA allele, dN/dS ratio between six regions of Known CD8+ T cell epitopes in the NS5B region. </plain></SENT>
</text></p><p><text><SENT sid="21737" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s004.docx"><caption><p><text><SENT sid="21738" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s005"><label>Table S5</label><caption><p><text><SENT sid="21739" pm="."><plain>Relationships of predicted CD4+ T cell epitopes of the NS5B with MHC class II HLA types prevalent in Korean population. </plain></SENT>
</text></p><p><text><SENT sid="21740" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s005.docx"><caption><p><text><SENT sid="21741" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s006"><label>Table S6</label><caption><p><text><SENT sid="21742" pm="."><plain>Quasispecies distribution at the codon 309 in 15 Korean patients. </plain></SENT>
</text></p><p><text><SENT sid="21743" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0087773.s006.docx"><caption><p><text><SENT sid="21744" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0087773-Chen1"><text><SENT sid="21745" pm="."><plain>1 ChenSL, MorganTR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3: 47–52.16614742 </plain></SENT>
</text></ref><ref id="pone.0087773-Soriano1"><text><SENT sid="21746" pm="."><plain>2 SorianoV, PetersMG, ZeuzemS (2009) New therapies for hepatitis C virus infection. Clin Infect Dis 48: 313–320.19123867 </plain></SENT>
</text></ref><ref id="pone.0087773-Tanaka1"><text><SENT sid="21747" pm="."><plain>3 TanakaY, NishidaN, SugiyamaM, KurosakiM, MatsuuraK, et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41: 1105–1109. </plain></SENT>
</text></ref><ref id="pone.0087773-Brown1"><text><SENT sid="21749" pm="."><plain>4 BrownRSJr, GaglioPJ (2003) Scope of worldwide hepatitis C problem. Liver Transpl 9: S10–13.14586889 </plain></SENT>
</text></ref><ref id="pone.0087773-Seeff1"><text><SENT sid="21750" pm="."><plain>5 SeeffLB (2002) Natural history of chronic hepatitis C. Hepatology. 36: S35–S46. </plain></SENT>
</text></ref><ref id="pone.0087773-Gerlach1"><text><SENT sid="21752" pm="."><plain>6 GerlachJT, DiepolderHM, ZachovalR, GruenerNH, JungMC, et al (2003) Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80–88.12851873 </plain></SENT>
</text></ref><ref id="pone.0087773-Liu1"><text><SENT sid="21753" pm="."><plain>7 LiuL, FisherBE, DowdKA, AstemborskiJ, CoxAL, et al (2010) Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 84: 5067–5077.20200239 </plain></SENT>
</text></ref><ref id="pone.0087773-Akuta1"><text><SENT sid="21754" pm="."><plain>8 AkutaN, SuzukiF, SezakiH, SuzukiY, HosakaT, et al (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372–380.16024941 </plain></SENT>
</text></ref><ref id="pone.0087773-Conjeevaram1"><text><SENT sid="21755" pm="."><plain>9 ConjeevaramHS, FriedMW, JeffersLJ, TerraultNA, Wiley-LucasTE, et al (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470–477.16890601 </plain></SENT>
</text></ref><ref id="pone.0087773-Missiha1"><text><SENT sid="21756" pm="."><plain>10 MissihaS, HeathcoteJ, ArenovichT, KhanK, Canadian Pegasys Expanded AccessG (2007) Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 102: 2181–2188. </plain></SENT>
</text></ref><ref id="pone.0087773-Fried1"><text><SENT sid="21758" pm="."><plain>11 FriedMW, ShiffmanML, ReddyKR, SmithC, MarinosG, et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.12324553 </plain></SENT>
</text></ref><ref id="pone.0087773-Ferrari1"><text><SENT sid="21759" pm="."><plain>12 FerrariE, HeZ, PalermoRE, HuangHC (2008) Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation. J Biol Chem 283: 33893–33901.18840605 </plain></SENT>
</text></ref><ref id="pone.0087773-Young1"><text><SENT sid="21760" pm="."><plain>13 YoungKC, LindsayKL, LeeKJ, LiuWC, HeJW, et al (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38: 869–878.14512874 </plain></SENT>
</text></ref><ref id="pone.0087773-Cheney1"><text><SENT sid="21761" pm="."><plain>14 CheneyIW, NaimS, LaiVC, DempseyS, BellowsD, et al (2002) Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology 297: 298–306.12083828 </plain></SENT>
</text></ref><ref id="pone.0087773-Hamano1"><text><SENT sid="21762" pm="."><plain>15 HamanoK, SakamotoN, EnomotoN, IzumiN, AsahinaY, et al (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. Journal of Gastroenterology and Hepatology 20: 1401–1409.16105128 </plain></SENT>
</text></ref><ref id="pone.0087773-Watanabe1"><text><SENT sid="21763" pm="."><plain>16 WatanabeK, YoshiokaK, YanoM, IshigamiM, UkaiK, et al (2005) Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: Their relation to viral load, response to interferon, and the nonstructural region 5A. Journal of Medical Virology 75: 504–512.15714488 </plain></SENT>
</text></ref><ref id="pone.0087773-Mo1"><text><SENT sid="21764" pm="."><plain>17 MoH, LuL, Pilot-MatiasT, PithawallaR, MondalR, et al (2005) Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49: 4305–4314.16189112 </plain></SENT>
</text></ref><ref id="pone.0087773-Plaza1"><text><SENT sid="21765" pm="."><plain>18 PlazaZ, SorianoV, GonzalezMD, Di LelloFA, MaciasJ, et al (2011) Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy 66: 2838–2842.21954459 </plain></SENT>
</text></ref><ref id="pone.0087773-Blackard1"><text><SENT sid="21766" pm="."><plain>19 BlackardJT, MaG, LimketkaiBN, WelgeJA, DryerPD, et al (2010) Variability of the polymerase gene (NS5B) in hepatitis C virus-infected women. J Clin Microbiol 48: 4256–4259.20810773 </plain></SENT>
</text></ref><ref id="pone.0087773-Yan1"><text><SENT sid="21767" pm="."><plain>20 YanKK, GuirgisM, DinhT, GeorgeJ, DevA, et al (2008) Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 14: 3416–3420.18528940 </plain></SENT>
</text></ref><ref id="pone.0087773-Heo1"><text><SENT sid="21768" pm="."><plain>21 HeoNY, LimYS, LeeHC, LeeYS, KimKM, et al (2013) High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clin Mol Hepatol 19: 60–69.23593611 </plain></SENT>
</text></ref><ref id="pone.0087773-Lyoo1"><text><SENT sid="21769" pm="."><plain>22 LyooK, SongMJ, HurW, ChoiJE, HongSW, et al (2011) Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 52: 363–366.21907615 </plain></SENT>
</text></ref><ref id="pone.0087773-Thomas1"><text><SENT sid="21770" pm="."><plain>23 ThomasDL, ThioCL, MartinMP, QiY, GeD, et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–U752.19759533 </plain></SENT>
</text></ref><ref id="pone.0087773-Ge1"><text><SENT sid="21771" pm="."><plain>24 GeD, FellayJ, ThompsonAJ, SimonJS, ShiannaKV, et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.19684573 </plain></SENT>
</text></ref><ref id="pone.0087773-Puoti1"><text><SENT sid="21772" pm="."><plain>25 PuotiC (2004) HCV carriers with persistently normal ALT Levels: not too much healthy, not true patients. Rom J Gastroenterol 13: 329–332.15624031 </plain></SENT>
</text></ref><ref id="pone.0087773-Sinn1"><text><SENT sid="21773" pm="."><plain>26 SinnDH, GwakGY, ShinJU, ChoiMS, LeeJH, et al (2013) Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World J Gastroenterol 19: 2256–2261.23599653 </plain></SENT>
</text></ref><ref id="pone.0087773-Lok1"><text><SENT sid="21774" pm="."><plain>27 LokAS, McMahonBJ (2007) Chronic hepatitis B. Hepatology 45: 507–539.17256718 </plain></SENT>
</text></ref><ref id="pone.0087773-Bruix1"><text><SENT sid="21775" pm="."><plain>28 BruixJ, CastellsA, BoschJ, FeuF, FusterJ, et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111: 1018–1022.8831597 </plain></SENT>
</text></ref><ref id="pone.0087773-DiLelio1"><text><SENT sid="21776" pm="."><plain>29 Di LelioA, CestariC, LomazziA, BerettaL (1989) Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 172: 389–392.2526349 </plain></SENT>
</text></ref><ref id="pone.0087773-Bruguera1"><text><SENT sid="21777" pm="."><plain>30 BrugueraM, BordasJM, MasP, RodesJ (1974) A comparison of the accuracy of peritoneoscopy and liver biopsy in the diagnosis of cirrhosis. Gut 15: 799–800.4279817 </plain></SENT>
</text></ref><ref id="pone.0087773-Bruix2"><text><SENT sid="21778" pm="."><plain>31 BruixJ, ShermanM, LlovetJM, BeaugrandM, LencioniR, et al (2001) Clinical management of hepatocellular carcinoma. </plain></SENT>
<SENT sid="21779" pm="."><plain>Conclusions of the Barcelona-2000 EASL conference. </plain></SENT>
<SENT sid="21780" pm="."><plain>European Association for the Study of the Liver. J Hepatol 35: 421–430.11592607 </plain></SENT>
</text></ref><ref id="pone.0087773-Nakatani1"><text><SENT sid="21781" pm="."><plain>32 NakataniSM, SantosCA, RiedigerIN, KriegerMA, DuarteCA, et al (2010) Development of hepatitis C virus genotyping by real-time PCR based on the NS5B region. PLoS One 5: e10150.20405017 </plain></SENT>
</text></ref><ref id="pone.0087773-Pawlotsky1"><text><SENT sid="21782" pm="."><plain>33 PawlotskyJM (2002) Use and interpretation of virological tests for hepatitis C. Hepatology. 36: S65–73. </plain></SENT>
</text></ref><ref id="pone.0087773-vanAsten1"><text><SENT sid="21784" pm="."><plain>34 van AstenL, VerhaestI, LamziraS, Hernandez-AguadoI, ZangerleR, et al (2004) Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis. Journal of Infectious Diseases 189: 292–302.14722895 </plain></SENT>
</text></ref><ref id="pone.0087773-Cuevas1"><text><SENT sid="21785" pm="."><plain>35 CuevasJM, Gonzalez-CandelasF, MoyaA, SanjuanR (2009) Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 83: 5760–5764.19321623 </plain></SENT>
</text></ref><ref id="pone.0087773-Uzicanin1"><text><SENT sid="21786" pm="."><plain>36 UzicaninS, HuYW, AlsousiH, PelchatM, RocheleauL, et al (2012) Hepatitis C virus: the role of molecular mimicry in response to interferon treatment. J Med Virol 84: 1571–1585.22930505 </plain></SENT>
</text></ref><ref id="pone.0087773-Ruhl1"><text><SENT sid="21787" pm="."><plain>37 RuhlM, KnuschkeT, SchewiorK, GlavinicL, Neumann-HaefelinC, et al (2011) CD8(+) T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins. Gastroenterology 140: 2064–2073.21376049 </plain></SENT>
</text></ref><ref id="pone.0087773-Hang1"><text><SENT sid="21788" pm="."><plain>38 HangJQ, YangY, HarrisSF, LevequeV, WhittingtonHJ, et al (2009) Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem 284: 15517–15529.19246450 </plain></SENT>
</text></ref><ref id="pone.0087773-Ludmerer1"><text><SENT sid="21789" pm="."><plain>39 LudmererSW, GrahamDJ, BootsE, MurrayEM, SimcoeA, et al (2005) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49: 2059–2069.15855532 </plain></SENT>
</text></ref><ref id="pone.0087773-Saitou1"><text><SENT sid="21790" pm="."><plain>40 SaitouN, NeiM (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406–425.3447015 </plain></SENT>
</text></ref><ref id="pone.0087773-Tamura1"><text><SENT sid="21791" pm="."><plain>41 TamuraK, DudleyJ, NeiM, KumarS (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596–1599.17488738 </plain></SENT>
</text></ref><ref id="pone.0087773-Mazumder1"><text><SENT sid="21792" pm="."><plain>42 MazumderR, HuZZ, VinayakaCR, SagripantiJL, FrostSD, et al (2007) Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes 35: 175–186.17508277 </plain></SENT>
</text></ref><ref id="pone.0087773-Chang1"><text><SENT sid="21793" pm="."><plain>43 ChangKM, ThimmeR, MelpolderJJ, OldachD, PembertonJ, et al (2001) Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33: 267–276.11124845 </plain></SENT>
</text></ref><ref id="pone.0087773-NeumannHaefelin1"><text><SENT sid="21794" pm="."><plain>44 Neumann-HaefelinC, Oniangue-NdzaC, KuntzenT, SchmidtJ, NitschkeK, et al (2011) Human Leukocyte Antigen B27 Selects for Rare Escape Mutations That Significantly Impair Hepatitis C Virus Replication and Require Compensatory Mutations. Hepatology 54: 1157–1166.22006856 </plain></SENT>
</text></ref><ref id="pone.0087773-Kobayashi1"><text><SENT sid="21795" pm="."><plain>45 KobayashiK, IshiiM, ShiinaM, UenoY, KondoY, et al (2005) Interferon-gamma is produced by CD8(+) T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clinical and Experimental Immunology 141: 81–88.15958073 </plain></SENT>
</text></ref><ref id="pone.0087773-Oh1"><text><SENT sid="21796" pm="."><plain>46 OhDJ, ParkYM, SeoYI, LeeJS, LeeJY (2012) Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors. Annals of Laboratory Medicine 32: 210–215.22563557 </plain></SENT>
</text></ref><ref id="pone.0087773-NeumannHaefelin2"><text><SENT sid="21797" pm="."><plain>47 Neumann-HaefelinC, McKiernanS, WardS, ViazovS, SpangenbergHC, et al (2006) Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 43: 563–572.16496339 </plain></SENT>
</text></ref><ref id="pone.0087773-Jaspe1"><text><SENT sid="21798" pm="."><plain>48Jaspe RC, Sulbaran YF, Sulbaran MZ, Loureiro CL, Rangel HR, et al. (2012) Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. </plain></SENT>
<SENT sid="21799" pm="."><plain>Virology Journal 9. </plain></SENT>
</text></ref><ref id="pone.0087773-Thio1"><text><SENT sid="21800" pm="."><plain>49 ThioCL, ThomasDL, GoedertJJ, VlahovD, NelsonKE, et al (2001) Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 184: 16–21.11398104 </plain></SENT>
</text></ref><ref id="pone.0087773-SchulzeZurWiesch1"><text><SENT sid="21801" pm="."><plain>50 Schulze Zur WieschJ, CiuffredaD, Lewis-XimenezL, KasprowiczV, NolanBE, et al (2012) Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209: 61–75.22213804 </plain></SENT>
</text></ref><ref id="pone.0087773-Grakoui1"><text><SENT sid="21802" pm="."><plain>51 GrakouiA, ShoukryNH, WoollardDJ, HanJH, HansonHL, et al (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659–662.14576438 </plain></SENT>
</text></ref><ref id="pone.0087773-Chung1"><text><SENT sid="21803" pm="."><plain>52 ChungHY, YoonJA, HanBY, SongEY, ParkMH (2010) [Allelic and haplotypic diversity of HLA-A, -B, -C, and -DRB1 genes in Koreans defined by high-resolution DNA typing]. Korean J Lab Med 30: 685–696.21157157 </plain></SENT>
</text></ref><ref id="pone.0087773-Minton1"><text><SENT sid="21804" pm="."><plain>53 MintonEJ, SmillieD, NealKR, IrvingWL, UnderwoodJC, et al (1998) Association between MHC class II alleles and clearance of circulating hepatitis C virus. </plain></SENT>
<SENT sid="21805" pm="."><plain>Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 178: 39–44.9652421 </plain></SENT>
</text></ref><ref id="pone.0087773-Kuzushita1"><text><SENT sid="21806" pm="."><plain>54 KuzushitaN, HayashiN, MoribeT, KatayamaK, KantoT, et al (1998) Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 27: 240–244.9425943 </plain></SENT>
</text></ref><ref id="pone.0087773-Ali1"><text><SENT sid="21807" pm="."><plain>55 AliL, MansoorA, AhmadN, SiddiqiS, MazharK, et al (2010) Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol 91: 1931–1938.20392899 </plain></SENT>
</text></ref><ref id="pone.0087773-Kim1"><text><SENT sid="21808" pm="."><plain>56Kim DW, Lee SA, Hwang ES, Kook YH, Kim BJ (2012) Naturally Occurring Precore/Core Region Mutations of Hepatitis B Virus Genotype C Related to Hepatocellular Carcinoma. </plain></SENT>
<SENT sid="21809" pm="."><plain>Plos One 7. </plain></SENT>
</text></ref><ref id="pone.0087773-NeumannHaefelin3"><text><SENT sid="21810" pm="."><plain>57 Neumann-HaefelinC, TimmJ, SchmidtJ, KerstingN, FitzmauriceK, et al (2010) Protective Effect of Human Leukocyte Antigen B27 in Hepatitis C Virus Infection Requires the Presence of a Genotype-Specific Immunodominant CD8+ T-Cell Epitope. Hepatology 51: 54–62.20034048 </plain></SENT>
</text></ref><ref id="pone.0087773-Liu2"><text><SENT sid="21811" pm="."><plain>58 LiuZ, RobidaJM, ChinnaswamyS, YiGH, RobothamJM, et al (2009) Mutations in the Hepatitis C Virus Polymerase that Increase RNA Binding Can Confer Resistance to Cyclosporine A. Hepatology. 50: 25–33. </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
